Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06151574 · ClinicalTrials.gov registry record · Phase 3
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
A Phase 3 study of Lung Cancer, Non-squamous, Non-small Cell, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 416
- Enrollment target
- 20
- Study locations
NCT06151574: Recruiting Phase 3 study of Lung Cancer, Non-squamous, Non-small Cell, sponsored by Boehringer Ingelheim.
NCT06151574 is a Phase 3 study of Lung Cancer, Non-squamous, Non-small Cell that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 416 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06151574, a Phase 3 study of Lung Cancer, Non-squamous, Non-small Cell, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 416 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib may slow cancer cell growth by inhibiting HER2. This would prolong cancer re-occurrence and increase survival. Current standard treatment is pembrolizumab plus platinum-pemetrexed chemotherapy. Participants are put into 2 groups by chance. One group receives zongertinib at regular times throughout the study and the other group receives infusions of pembrolizumab, pemetrexed and cisplatin or carboplatin (pembrolizumab plus platinum-pemetrexed chemotherapy) into a vein. Participants may be in the study up to a maximum of 70 months. During this time, they visit the study site about every 3 weeks for study procedures. The doctors regularly check the size of the tumour with a CT or MRI scan, at the beginning of the study and every 6 weeks. After 18 months they check the tumour size every 12 weeks. Doctors regularly check whether the cancer has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects. The time it takes for the cancer to worsen is compared between the 2 groups to see whether the treatment works. The participants also fill in questionnaires about their symptoms and quality of life.
Primary Outcome
PFS is defined as the time from randomization until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG cisplatin
- DRUG carboplatin
- DRUG pemetrexed
- DRUG zongertinib
Study Locations (20)
California
- Precision NextGen Oncology - Beverly Hills
- ClinRé 001-022 (Premier Cancer Care and Infusion Center) - Fresno
- OPN Healthcare, Inc. - Glendale
- Scripps Green Hospital - La Jolla
- Valkyrie Clinical Trials - Los Angeles
- Sharp Memorial Hospital - San Diego
Missouri
- St. Louis Cancer Care, LLP - Bridgeton
- Oncology Hematology Associates - Springfield
New York
- Northwell Health - Lake Success
- Montefiore Medical Center - The Bronx
Alabama
- Clearview Cancer Institute - Huntsville
Arizona
- Pioneer Research Center - Bullhead City - Bullhead City
Nevada
- Cancer Care Specialists - Reno
North Carolina
- Regional Medical Oncology Center - Wilson
Ohio
- Gabrail Cancer Center - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2024-02-09 |
| Est. Completion | 2028-01-28 |
| Phase | Phase 3 |
What NCT06151574 shows while recruiting
NCT06151574 is an interventional study that assigns participants to a tested intervention. The registered 416 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Lung Cancer, Non-squamous, Non-small Cell appearing as the primary indexed condition, and to 5 interventions - of which pembrolizumab is the first listed.
NCT06151574 names 20 study sites across 13 states, led by California, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT06151574 about?
NCT06151574 is a clinical study titled "Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment". This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this...
What is the current status of trial NCT06151574?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 416 participants. The study started on 2024-02-09. Estimated completion is 2028-01-28.
What conditions does trial NCT06151574 study?
This clinical trial studies the following conditions: Lung Cancer, Non-squamous, Non-small Cell.
What interventions are being tested in trial NCT06151574?
The interventions under investigation include: pembrolizumab (DRUG), cisplatin (DRUG), carboplatin (DRUG), pemetrexed (DRUG), zongertinib (DRUG).
Who is sponsoring clinical trial NCT06151574?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06151574 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06151574's enrollment target sits among peer trials
416 903rd of 2000 higher than 1,098 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
- NCT05007782 · 416 participants · Phase 1
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
- NCT05520099 · 416 participants
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
- NCT06075745 · 416 participants · Phase 2
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI